Luminex (NASDAQ:LMNX) announces Q2 2020 revenues between $109M and $110M, up more than 30% over Q2 2019.
Molecular Diagnostics revenue of ~$65M, up over 100% vs. Q2 2019.
Sample-to-answer MDx revenue of ~$30M, (+65% Y/Y).
Automated and Non-automated MDx assay revenue of ~$26M and ~$35M, respectively.
170 sold or contracted sample-to-answer systems.
Licensed Technologies Group revenue of ~$35M.
Flow Cytometry revenue of more than $7M.
The company had an additional $2M of confirmed orders that were not able to be installed due to the COVID-19.
Luminex expects to release full Q2 results on August 3.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.